Last reviewed · How we verify
Tinea barbae — Treatment Landscape & Competitive Intelligence
5 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Grifulvin V | GRISEOFULVIN | Johnson And Johnson | Tubulin Inhibiting Agent [EPC] | Solute carrier family 22 member 1 | 1962-01-01 | |
| FULVICIN P/G 330 | GRISEOFULVIN, ULTRAMICROSIZE | CHARTWELL RX | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin | |||
| GRISEOFULVIN | GRISEOFULVIN, MICROSIZE | COSETTE | Tubulin Inhibiting Agent [EPC] | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin | ||
| GRISACTIN ULTRA | GRISEOFULVIN, ULTRAMICROCRYSTALLINE | WYETH AYERST | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin | |||
| GRIFULVIN V | GRISEOFULVIN, MICROCRYSTALLINE | JOHNSON AND JOHNSON | Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- CHARTWELL RX · 1 drug in Tinea barbae
- COSETTE · 1 drug in Tinea barbae
- JOHNSON AND JOHNSON · 1 drug in Tinea barbae
- Johnson And Johnson · 1 drug in Tinea barbae
- WYETH AYERST · 1 drug in Tinea barbae
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Tinea barbae:
- Tinea barbae treatment updates — RSS
- Tinea barbae treatment updates — Atom
- Tinea barbae treatment updates — JSON
Cite this brief
Drug Landscape (2026). Tinea barbae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tinea-barbae. Accessed 2026-06-10.
Related
- Tinea barbae full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing